Bausch + Lomb (BLCO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $630M

Overview

Bausch + Lomb is a leading, pure-play eye health company with a mission to protect and enhance sight globally. Its strategic separation from Bausch Health in 2022 unlocked its potential to focus on the high-growth dynamics of the vision care market. The company's strength lies in its integrated portfolio across Vision Care, Pharmaceuticals, and Surgical segments, supported by significant R&D in material science and drug delivery. Its strategy is centered on innovation, geographic expansion, and leveraging its trusted brand to capitalize on powerful demographic tailwinds.

OphthalmologyVision Care

Technology Platform

Integrated expertise across ophthalmic material science (silicone hydrogel contact lenses), pharmaceutical formulation for anterior/posterior eye delivery, and surgical device & intraocular lens (IOL) design platforms.

Funding History

1

Total raised:$630M

IPO$630MUndisclosedMay 6, 2022

Opportunities

Powerful demographic tailwinds from an aging global population and rising myopia rates drive sustained demand across all segments.

The company is well-positioned to capitalize on premiumization trends in surgical (advanced IOLs) and vision care (silicone hydrogel daily disposables), while geographic expansion in emerging markets offers a long-term growth runway.

Risk Factors

Intense competition, particularly from larger rival Alcon in surgical, creates pricing pressure and demands continuous high-level innovation.

Regulatory hurdles and reimbursement decisions for new products pose significant commercial risks, while the company's post-spin financial execution, including debt management, remains a key focus.

Competitive Landscape

Bausch + Lomb competes in fragmented but tough markets: against J&J Vision, Alcon, and CooperVision in Vision Care; against Novartis/Alcon and AbbVie in Pharmaceuticals; and as a strong #2 against dominant leader Alcon in Surgical. Its full-spectrum portfolio and global brand are key differentiators.

More companies in Small Molecule Drugs →More companies in United States →